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accepted July 30, 2espite improvements in interventional and pharmacological therapy of atherosclerotic disease, it is still the leading
cause of death in the developed world. Hence, there is a need for further development of effective therapeutic
approaches. This requires better understanding of the molecular mechanisms and pathophysiology of the disease.
Atherosclerosis has long been identiﬁed as having an inﬂammatory component contributing to its pathogenesis,
whereas the available therapy primarily targets hyperlipidemia and prevention of thrombosis. Notwithstanding
a pleotropic anti-inﬂammatory effect to some therapies, such as acetyl salicylic acid and the statins, none of the
currently approved medicines for management of either stable or complicated atherosclerosis has inﬂammation as
a primary target. Monocytes, as representatives of the innate immune system, play a major role in the initiation,
propagation, and progression of atherosclerosis from a stable to an unstable state. Experimental data support a role
of monocytes in acute coronary syndromes and in outcome post-infarction; however, limited research has been done
in humans. Analysis of expression of various cell surface receptors allows characterization of the different monocyte
subsets phenotypically, whereas downstream assessment of inﬂammatory pathways provides an insight into their
activity. In this review we discuss the functional role of monocytes and their different subpopulations in
atherosclerosis, acute coronary syndromes, cardiac healing, and recovery with an aim of critical evaluation of
potential future therapeutic targets in atherosclerosis and its complications. We will also discuss technical
difﬁculties of delineating different monocyte subpopulations, understanding their differentiation potential and
function. (J Am Coll Cardiol 2013;62:1541–51) ª 2013 by the American College of Cardiology FoundationAtherosclerosis accounts for one-ﬁfth of all deaths in the
world (1). It is the leading cause of death in the United
Kingdom, with more than 600,000 deaths annually due to its
complications (1). Acute coronary syndrome (ACS) is an
acute pathology associated with atherosclerotic plaque
rupture and interruption of coronary blood supply to my-
ocardial tissue. Acute coronary syndrome carries a high
mortality rate both en route to the hospital and after receiving
treatment. Acute coronary syndrome is also associated
with high morbidity, especially when heart failure develops
due to extensive myocardial damage. Hence, ACS forms an
important ﬁeld for research with an obvious need for
improvement of current medical management and intro-
duction of new therapeutic targets. Better understanding of
the underlying pathophysiological mechanisms leading to
plaque development and rupture is essential to meet this need.rsity of Birmingham Centre for Cardiovascular Sciences, City
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013.Inﬂammation clearly contributes to the pathophysiology
of atherosclerosis. Infectious agents, such as Chlamydia
pneumoniae, have been detected in coronary atherosclerotic
lesions (2). Human atherosclerotic plaques contain viruses as
well as numerous bacterial signatures, including nucleic acids,
and peptidoglycan (3). In addition, several studies suggest
positive associations between oral bacterial colonization-
levels and increased risk of atherosclerosis (e.g., coronary
artery disease [CAD]) and cerebrovascular events (4,5),
supporting the link between atherosclerosis and an inﬂam-
matory/infective pathophysiology (5,6). The low-grade
inﬂammation associated with CAD is acknowledged in
day-to-day clinical practice, with an American Heart Asso-
ciation/Center for Disease Control consensus report (7)
recommending measurement of C-reactive protein in
asymptomatic subjects at intermediate risk for future
coronary events (10-year risk of 10% to 20%) and in selected
patients after an ACS (7). In fact, JUPITER (Justiﬁcation for
the Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin) trial indicated that statin
therapy might reduce numbers of adverse cardiovascular
events in subjects with normal low-density lipoprotein
(LDL) range but high C-reactive protein concentrations.
Abbreviations
and Acronyms
ACS = acute coronary
syndrome
CAD = coronary artery
disease
DC = dendritic cells
Ig = immunoglobulin
IL = interleukin
LDL = low-density lipoprotein
MCP = monocyte
chemoattractant protein
MI = myocardial infarction
MMP = matrix
metalloproteinase
ROS = reactive oxygen
species
TGF = transforming growth
factor
TNF = tumor necrosis factor
VEGF = vascular endothelial
growth factor
Ghattas et al. JACC Vol. 62, No. 17, 2013
Monocytes in Atherosclerosis October 22, 2013:1541–51
1542Although it is pertinent to note
that LDL levels were lower
in intervention compared with
placebo groups, an anti-
inﬂammatory role of LDL low-
ering cannot be excluded (8). The
ongoing CANTOS (Canakinu-
mab Anti-Inﬂammatory Throm-
bosis Outcomes Study) and
CIRT (Cardiovascular Inﬂamma-
tion Reduction Trial) trials di-
rectly investigate the potential role
of anti-inﬂammatory therapies in
reducing vascular events, both on
a secondary and primary basis,
respectively. Further evidence for
the importance of inﬂammation
in cardiovascular disease is seen
from the ruptured plaque his-
tology with abundance of macro-
phages, a thin ﬁbrous cap, and
smooth muscle cell loss due to
apoptosis (9).The innate immune system plays a major role in the
initiation and propagation of atherosclerosis, with mono-
cytes/macrophages being the key players in this process (10).
Monocyte involvement in the development of atheroscle-
rotic plaques was reported in the 1970s, with monocyte
accumulation demonstrated in porcine atherosclerotic
lesions (11).
Three indirectly related processes, which involve mono-
cytes, have been identiﬁed in atherosclerosis (Fig. 1).
Monocytes have been shown to play a role:
1. During the long-term process of initiation and
formation of an atherosclerotic plaque, presumed to be
accelerated by different risk factors, including
smoking, hypertension, hyperglycemia, and critically
hyperlipidemia;
2. During the acute inﬂammatory phase that follows
destabilization, rupture of the atherosclerotic plaque,
and acute thrombus formation in ACS; and
3. During healing, where they reside in the myocardial
tissue in the hypoxic phase during an acute coronary
event and might promote myoﬁbroblast accumulation,
angiogenesis, and myocardial healing and remodeling,
thus showing a protagonist or antagonist inﬂuence in
post-ACS recovery.
In the present review, we critically examine these 3 roles
of monocytes and evaluate data on the modulation of
monocyte function indicating the future direction of novel
therapeutic interventions. Several characteristic features of
monocytes are important in explaining this multitude of
actions, namely, varying subpopulations, high plasticity and
trafﬁcking capacity, and existence of multiple reservoirs and
hematopoietic maturation sites.How Can the Diversity of
Monocyte Functions Be Explained?
Monocytes account for 3% to 8% of peripheral blood leuko-
cytes. They are mononuclear cells often characterized by
typical kidney-like shaped nuclei, but they are more accu-
rately described by their expression of various surface recep-
tors (12). They are the main component of the innate
immune system that is responsible for counteracting exoge-
nous bacterial, viral, and fungal infections mainly by phago-
cytosis (13). However, they are also involved in endogenous
inﬂammatory processes. Monocytes contribute to athero-
genesis through promoting leukocyte recruitment to plaques,
and their roles are also mediated by activation of downstream
signaling pathways, such as nuclear factor kappa-B pathway
(14). Indeed, monocytes have been directly implicated in
a number of chronic inﬂammatory conditions, including
glomerulonephritis, rheumatoid arthritis, lung ﬁbrosis, and
atherosclerosis (15,16).
Cell surface receptor expression allows discrimination
between monocyte subpopulations and was ﬁrst described in
murine models. Palframan et al. (17) and Geissmann et al.
(18), with CX3CR1 knockout mice, demonstrated that
peripheral blood monocytes differ in CX3CR1, CCR2, and
CD62L expression. Monocytes expressing CCR2, CD62L,
and low levels of CX3CR1 seemed to be preferentially
recruited to inﬂamed sites by virtue of their recognition
of CCL2 (monocyte chemoattractant protein [MCP]-1).
Conversely, the CX3CR1high monocytes could migrate
into non-inﬂamed sites (18) or migrate later during the
recovery period after an acute inﬂammation (19).
In humans, “classical” monocytes, which represent 80% to
85% of the total population of circulating blood monocytes,
can be identiﬁed by high expression of CD14 and lack of
CD16 expression (also referred as Mon1). They are consid-
ered inﬂammatory mediators and represent the predominant
subpopulation identiﬁed in atherosclerotic plaques (20).
These monocytes also express CCR2, CD62L, and CD64
(21). The migration of this subpopulation depends strongly
on MCP-1 secreted by resident macrophages (22).
Another human monocyte subset is deﬁned as the
CD14þCD16þþ cells, and it is referred to as “non-
classical” monocytes or Mon3 population. They express high
levels of CX3CR1 but do not express CCR2 or CD62L
(23,24). This subtype depends on fractalkine (or CX3CL1,
a soluble chemokine-like domain) for attraction and re-
cruitment to endothelial surfaces. Fractalkine is expressed on
activated endothelial cells as a transmembrane-anchored
adhesion receptor, thus attracting and arresting monocytes
from the circulation into the atherosclerotic plaque. Indeed,
CX3CR1 knockout mice fed on a high-fat diet showed
a signiﬁcant reduction in monocyte recruitment to the
vascular wall and reduced atherosclerotic plaque formation.
In fact, genetic deletions of CCL2, CX3CL1, or their
cognate receptors, CCR2 and CX3CR1, markedly reduced
atherosclerotic lesion size in murine models of atherosclerosis
Figure 1 Triple Role of Monocytes at Different Stages of the Atherosclerotic Process
The 3 panels depict the functions of monocytes. Monocytes patrolling in the circulation are activated by different factors. They trafﬁc to the damaged/activated endothelium. The
dysfunctional endothelium over-express monocyte chemotactic protein-1 ligand and adhesion molecules (vascular cell adhesion molecule [VCAM]-1, intercellular adhesion
molecule [ICAM]-1) on its surface. After rolling and attachment to the endothelium, the monocytes cross the endothelial surface (diapedesis). In the subendothelial space
monocytes differentiate to macrophages via macrophage colony stimulating factor. The macrophages ingest oxidized low-density lipoprotein (LDL) via scavenger receptors,
especially CD36, forming “foam” cells. These undergo a process of apoptosis/necrosis that perpetuates the formation of further lipid-laden macrophages. The middle panel
depicts events during an acute coronary syndrome with plaque rupture, thinning of the ﬁbrous cap on plaque surface, and monocyte platelet aggregates. The right panel
illustrates cardiac repair, acutely with attraction of monocytes CD14þþCD16–CCR2þ (Mon1) and later in the phase 2 of remodeling where CD14þCD16þþCCR2 (Mon3)
(and potentially CD14þþCD16þCCR2þ (Mon2) cells) alters the extracellular matrix remodeling by myoﬁbroblast deposition and angiogenesis, leading to thinning of
the infarcted cells. CCR ¼ CC chemokine receptor; JAM ¼ junctional adhesion molecule; MCP ¼ monocyte chemoattractant protein; MMP ¼ matrix metalloproteinase;
RANTES ¼ regulated upon activation, normal T-cell expressed and secreted.
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1543(25). When the 3 chemokine receptors CCR5, CCR2, and
CX3CR1 were blocked, the maximal reduction in the
atherosclerotic plaque formation was evident, suggesting that
all monocyte subpopulations are involved in atherogenesis
(26). Table 1 summarizes the characteristics of different
monocyte subsets in humans and in mice.
Differences between monocyte subpopulation functions
have been exempliﬁed in an elegant in vivo mouse study by
Auffray et al. (27), who postulated that non-classical/resident
monocytes constantly patrol healthy tissues through long-
range crawling along the endothelium. During acute
inﬂammation these monocytes use CX3CR1 and the integrin
lymphocyte function-associated antigen-1 to “home” on the
inﬂamed tissues on an “as required basis.” In humans, Cros
et al. (28) indicated that CD14 low (i.e., CD14þCD16þþ)
“non-classical” monocytes also have similar patrolling prop-
erties and are involved in the innate local surveillance of
tissues and the pathogenesis of autoimmune diseases.More recently, a third human monocyte subpopulation
has been identiﬁed as “intermediate” CD14þþCD16þ
(also called Mon2) cells (29). They are reported to be a
predominant type of monocytes expressing Tie-2 (an
angiopoietin receptor), which has been implicated in angio-
genesis. The presence of the 3 distinct monocyte subsets
was recently conﬁrmed by gene microarray analysis (21,29).
The “intermediate” subset has the highest expression of
major histocompatibility complex class II molecules, whereas
“non-classical” CD14þCD16þþ monocytes are character-
ized by high expression of cytoskeletal re-arrangement
genes, inﬂammatory cytokines, and CD294 (21).
The varying nomenclature used to describe monocytes
poses a problem in uniﬁed interpretation of animal and
human data. Because most of the current knowledge in the
ﬁeld originates from murine models, effort is directed toward
establishment of parallels between monocyte subsets across
species. Scarce information on their functions adds to the
Table 1 Comparison of Different Monocyte Subpopulations Phenotype and Functions
Characteristic Inﬂammatory/Classical Newly Described Intermediate Population Resident/Nonclassical
Human CD14þþCD16CCR2þ CX3CR1lo;





Mice Ly6-Chi, CCR2þ, CXCR1lo, CD62Lþ,
CD115þ, CD11, MHC class II ve
No distinct model is available; however,
has characteristics of Ly6-Chi models
Ly6Clow, CX3CR1hi, CD62L,
CD115, MHC- class II þve
Recruitment Early in acute inﬂammation Early in acute inﬂammation Late in acute inﬂammation
Reservoirs Spleen None known Unknown
Function Acute Accumulate in injured myocardium
and perform inﬂammatory and
proteolytic function
? Inﬂammation Assumed role in granulation tissue
formation and angiogenesis,
later mobilization
Chronic Accumulate in atherosclerotic plaque
in response to activated endothelium.
Given high expression of CD163 and CD204
scavenger receptors then accumulation in
atherosclerotic plaque is possible
Accumulate in atherosclerotic
plaque via CCR5 and CX3CR1
MHC ¼ major histocompatibility complex; VCAM ¼ vascular cell adhesion molecules.
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1544complexity of drawing reliable conclusions on the physio-
logical and pathological roles of monocyte subsets in humans.
For example, features of the so-called “intermediate” subsets
are increasingly demonstrated and recognized in a wide range
of pathological conditions. An “intermediate” pattern of the
subset might be partly due to some overlap with other subsets
(particularly with “non-classical” monocytes), when their
deﬁnition is solely based on their CD14 and CD16 expres-
sion. More accurate delineation of CD14þþCD16þ and
CD14þCD16þþ monocytes can be achieved by addition-
al marker CCR2 (29), with “intermediate” monocytes
being “CD14þþCD16þCCR2þ” and “non-classical”
monocytes being “CD14þCD16þþCCR2.” Of note,
CD14þþCD16þ monocytes show the highest of all
monocyte expression of many surface receptors, particularly
those involved in reparative processes (e.g., CXCR4, Tie2,
vascular endothelial growth factor [VEGF] receptors type 1
and 2). This, together with the evidence of speciﬁc enrich-
ment of this subset in bone marrow, indicates that it is
unlikely to just represent an “intermediate” state between the
other 2 subsets but rather a unique and distinct monocyte
subpopulation. Although it is not yet entirely clear whether
speciﬁc monocyte subsets are pre-determined to differentiate
into particular types of tissue macrophages and dendritic
cells (DC), published data suggest existence of common
features and links between CD14þþCD16– (Mon1) and
CD14þþCD16þ (Mon2) monocytes and M1 and M2
polarized macrophages, respectively. Also in vivo, Ly-6Clo
and Ly-6Chi monocytes from mice differentiate more readily
into M2-like cells and M1-like macrophages, respectively,
but macrophage development also depends on surrounding
microenvironment and interaction(s) with other cell types,
such as lymphocytes (30,31). Accordingly, the assignment of
numerical dominators (i.e., Mon1, Mon2, and Mon3) for
human monocyte subsets might not be appropriate until
more data are available on the relationships between the subsets.
Monocyte Trafﬁcking and Developmental Plasticity
High trafﬁcking ability is another characteristic feature of
monocytes. A hallmark of monocyte trafﬁcking is thecapacity of monocytes to traverse from the circulation into
areas of injury/inﬂammation, aiming for resolution of
infection and contribution to the restoration of the tissue
integrity via differentiation of different types of tissue
macrophages and DC. However, presumably “reparative”
properties of the monocytes might fail and lead to a disease
state, with atherosclerosis being an example. Indeed,
monocytes are precursors of lipid-laden “foam” cell macro-
phages, which are a critical component of atherosclerotic
plaques. Even mature monocyte-derived macrophages do
not lose their mobility entirely, under certain circumstances
(which are not entirely understood) monocyte/macrophages,
including “foam cells” can migrate from the vascular wall
back into the circulation (31). In several studies monocyte
migration from atherosclerotic plaques led to plaque
regression under experimental conditions (32,33). In a
mouse model, statin therapy augmented the egression of the
plaque macrophages via removing the inhibitory effect on
CCR7 and independently of lipid levels (34), possibly rep-
resenting an additional pleiotropic effect of statins.
Monocytes are also characterized by an extremely high
developmental plasticity, being able to differentiate under
appropriate stimulation into different cell types ranging from
epithelial, endothelial, cartilage cells to functional ﬁbro-
blasts, cardiomyocytes, and neuronal cells. Most of this work
has been done under experimental conditions, and the
in vivo and (more importantly) clinical relevance is only
beginning to emerge (as discussed in the following text).
More information on the role of monocytes in atheroscle-
rotic plaque development and progression can be found in
the Online Appendix, including Online Table 1.
Monocytes in the ACS
Acute coronary syndrome refers to a clinical spectrum
ranging from those for ST-segment elevation myocardial
infarction (STEMI) to non-STEMI or unstable angina
(35,36). Acute coronary syndrome is almost always associ-
ated with rupture of an atherosclerotic plaque and partial or
complete thrombosis of the infarct-related artery. Most cases
of ACS occur from disruption of a previously non-occlusive
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1545but unstable (vulnerable) plaque (37,38). The characteristic
features of a vulnerable plaque include a thin ﬁbrous cap,
a higher predominance of macrophages in the cap, smaller
collagen content, and a large, lipid-rich necrotic core with
overlying thrombus and platelet aggregates (39).
Monocytes promote destabilization of the ﬁbrous cap
leading to the plaque rupture. This is mainly orchestrated
by matrix metalloproteinases (MMPs) (40,41). Activated
macrophages produce a wide range of lytic enzymes,
including MMPs (e.g., MMP-1, -2, -3, -8, -9, and -14)
(42). Increased expression and activity of MMPs has been
noted in vulnerable plaque regions, whereas elevated
serum MMPs have been demonstrated in patients with
ACS (43).
Plaque rupture could lead to downstream occlusion of
coronary ﬂow to the myocardium, the principle mechanism
of STEMI. Monocytes have a role in thrombus propagation
contributing to the coagulation cascade during the acute
event. Patients with ACS show features of procoagulant
monocyte activation with exposure of tissue factor (44).
Monocyte-platelet aggregates, and markers of monocyte
and platelet activation involved in regulation of their func-
tion are also increased in ACS patients, persisting even after
one month of the acute event (45). Also, microparticles
derived from monocytes are abundant in ACS and support
faster ﬁbrin formation (46).
Monocyte adherence to extracellular matrix and extrava-
sation to the injured tissue induces the expression of
a multitude of cytokines, including tumor necrosis factor
(TNF)-a, interleukin (IL)-1 and IL-6 (potent inﬂammatory
cytokines); platelet-derived endothelial cell growth factor (a
potent chemoattractant and mitogen for ﬁbroblasts); trans-
forming growth factor (TGF)-a and -b (which contributes
to ﬁbrosis, by stimulating extracellular matrix release,
primarily collagen, from myocardial ﬁbroblasts); macrophage
colony-stimulating factor (cytokine necessary for macro-
phage survival), and insulin-like growth factor (47,48).
Monocytes are also thought to participate in tissue injury.
Downstream occlusion of blood supply to the myocardium
(ischemia) followed by pharmacological or interventional
revascularization therapy (reperfusion) results in the
ischemia-reperfusion cascade. During hypoxia, reactive
oxygen species (ROS) leakage from mitochondria is
increased (49). The ROS-modiﬁed biomolecules formed
during ischemia stimulate inﬁltration of inﬂammatory cells,
including monocytes, thus mediating an acute inﬂammatory
response leading to cell injury and necrosis. Recently, a new
model of “innate autoimmunity” for ischemia/reperfusion
injury has been introduced, which integrates mechanisms of
both intrinsic ischemic cell injury and initiation of an
extrinsic innate immune response (50). This hypothesis that
the intrinsic changes associated with cell injury are
augmented by a second wave of the innate immune system
involvement largely represented by monocytes (e.g., medi-
ated by the complement system, immunoglobulin [Ig] M
and their receptors) helps to explain the continued loss ofmyocytes despite reperfusion and, in some in vitro studies,
despite elimination of inﬂammatory cells (51).
Within the subintimal space, monocytes mature into DC
and macrophages, each with its separate polarity, and
inﬂammatory functions that have further effect on tissue
necrosis (30). Macrophages are currently considered to
comprise 2 types: the classically activated (pro-inﬂammatory
M1 type); and the alternatively activated M2 acting as anti-
inﬂammatory cells (47). The M1 macrophages promote
inﬂammation and extracellularmatrix destruction. The IL-1b
secretion from M1 induces MMP-9 and TGF-b secretion
and stimulates ﬁbroblast proliferation (47). Macrophage
phagocytosis of dying cells also triggers TGF-b production
(52).Of interest, inmurinemodels, monocyte tissue residence
time was found only to be approximately 20 h, with persis-
tently high rates of recruitment to infarcted myocardium days
after the acute event and disproportionally slower rate of
exiting from infarcted tissues at a maximum rate of 13%/day
(53).
A mouse model of myocardial infarction (MI) has
demonstrated substantial functional differences between
monocyte subsets in the course of the infarction. For instance,
mice Ly-6Chi monocytes (considered to be equivalent to
CD14þþCD16–CCR2þ human cells) are mobilized early
after MI onset and show distinct phagocytic properties. In
contrast Ly-6Clo monocytes (considered to be the equivalent
of human CD14þCD16þþCCR2 cells) showed anti-
inﬂammatory properties and were critical for myocardial
healing and reverse remodeling in MI, promoting myoﬁ-
broblast accumulation, angiogenesis, and the deposition of
collagen (19). The production of these subsets seemed to
follow a biphasic mode, with an early release of Ly-6Chi
followed by a later production of Ly-6Clo (19).
At the other end of the monocyte differentiation spec-
trum, levels of circulating DC (both plasmacytoid as well as
myeloid DC) have been found to be signiﬁcantly reduced in
patients after an ACS, compared with healthy control
subjects (54). It is thought that this is due to increased
recruitment of DC to the infarcted tissue. This hypothesis
was supported with immunohistochemistry ﬁndings indi-
cating an increase in the DC and T-cell inﬁltration of peri-
infarct zone (55).
Monocytes and Cardiac Remodeling
Despite advances in medical and interventional therapy for
ACS, many patients still develop heart failure. The process of
post-MI myocardial recovery depends on numerous factors at
the cellular and molecular levels. After the initial tissue
damage induced by hypoxia, an acute inﬂammatory response
ensues with recruitment of leukocytes to the infarcted areas
(19). Subsequent release of ROS, phagocytosis, ﬁbroblast
accumulation, angiogenesis, and tissue formation occurs,
ultimately leading to cardiac remodeling and recovery
modulated by the activity of these recruited cells. The role of
inﬂammation is important. For example, an increase of the
Ghattas et al. JACC Vol. 62, No. 17, 2013
Monocytes in Atherosclerosis October 22, 2013:1541–51
1546pro-inﬂammatory cytokine TNF-a with a corresponding
decrease of anti-inﬂammatory cytokine IL-10 is associated
with adverse/reverse ventricular remodeling (56). Together,
leukocytes degrade extracellular matrix constituents and
macromolecules released by the injured cells and aid
clearance of dead cardiomyocytes and their debris.
Historically, monocytosis has been associated with left
ventricular dysfunction post-MI, with recruited monocytes
releasing multiple cytokines, such as IL-1a and -1b, IL-6,
and TNF-a, which are negatively associated with myocar-
dial healing and development of heart failure (57). The
balance between removing dead myocytes and prompt
initiation of regeneration might determine patient outcomes.
Monocyte injection and their cardiac recruitment through
MCP-1, IGF-1 secretion, enhanced remodeling with
improved post-MI cardiac contractility in mice (58).
Monocytes are also involved in myocardial ﬁbrosis and post-
infarction scar formation, whereas their release of angiogenic
factors (e.g., VEGF) promotes angiogenesis in and around
the healing tissue.
Of note, prolonged Ly-6Chi monocytosis early after MI
onset could impair myocardial healing in a murine model
(59,60). By contrast, depletion of Ly6Chi monocytes early
post-infarct led to increased areas of debris and necrotic
tissue with impaired ventricular healing (19). This accords
with results of a previous murine study where post-infarct
macrophage depletion led to ventricular dilation and
myocardial wall thinning with concurrent decrease in neo-
vascularization, myoﬁbroblast, and collagen depositions (61).
Recently, depletion of DC led to a similar result, with sus-
tained expression of inﬂammatory cytokines such as IL-1b,
TNF-a, IL-18, and MMP-9 as well as a decrease in IL-10
within the infarcted area in a mouse model. Interestingly,
there was an increase in Ly6Chi monocytes in DC-depleted
mice (62). It could be postulated that this is due to inter-
ruption of DC-induced “negative feedback” on differentia-
tion signaling that controls monocyte subpopulations/
macrophage interaction. Hence, depleting DC might lead to
uncontrolled monocyte differentiation and disruption of this
phagocytic system, thus illustrating the intricate balance and
cross talk between different components.
However, our knowledge of the effect of monocytes on
cardiac remodeling and clinical outcome in humans is still
limited. Although similarities exist in MI pathophysiology
between species, the inter-species differences between
monocyte subsets are substantial (including that monocytes
account for 50% of murine leukocytes vs. a much smaller
proportion in humans). This might make extrapolation of
animal data to humans challenging from a clinical and
pharmaceutical perspective (63).
The effect of monocytes on ventricular healing in humans
has been investigated in 1 small study, where numbers of
CD14þCD16– monocytes were negatively associated with
myocardial salvage after STEMI and poor clinical outcome
(64). The CD16þ monocytes (analyzed as a mixture or
“intermediate” and “non-classical” monocytes) had no effecton ventricular remodeling, which contrasted with previous
animal data (19). In a recent study where levels of the 3
human monocyte subsets in STEMI were analyzed sepa-
rately a prominent (over 2.5-fold) up-regulation of the
CD14þþCD16þCCR2þ (Mon2) (described elsewhere in
the published data as intermediate monocytes) subset in
acute STEMI was observed with no changes in
CD14þCD16þþCCR2 (Mon3) cells (45). This was
accompanied by a signiﬁcant change in phenotype of the
“intermediate” subset (increase in CD14 and CCR2
expression, and a reduction in CD16 expression). These
observations of distinctive changes related to this subset
together with existing evidence of their pro-reparative and
pro-angiogenic phenotype and anti-inﬂammatory properties
are suggestive of their possible speciﬁc roles in cardiac
recovery, but sufﬁciently powered data in this respect are
lacking.
Interest in the “intermediate” monocytes has been echoed
in a number of clinical studies that indicated that their high
levels have been associated with poor clinical outcome both
in terms of future MI in stable coronary artery disease (the
HOM SWEET HOMe [Heterogeneity of Monocytes in
Subjects Who Undergo Elective Coronary Angiogra-
phydThe Homburg evaluation] study) (65) and lower left
ventricular ejection fraction in patients post-STEMI (66) or
as recurrence of coronary events in patients with chronic
kidney disease and in stroke patients (67,68). The biological
roles of this subset are complex, and expression of receptors
with a putative role in angiogenesis and repair (e.g., VEGF
receptor-2, CD163, and CXCR4, which was found to be
relevant to STEMI) are highest in this subset (69). One
might speculate that the intermediate monocyte subset
might play a role in myocardial reparation post-MI.
However, the cause of such associations remains unclear,
and the exact function of the intermediate monocytes is still
under investigation. Currently our knowledge only extends
to very limited functional studies and a number of descrip-
tive surface and genetic markers (to mention a few: CCR5,
VEGF receptor 2, HLA-DR, ENG, CLEC10A, ACE,
GFRA2) (21,70). It is still unclear whether this subpopu-
lation is a separate and independent entity from Mon1 and
Mon2 and, hence, has its own differentiating pathway or
whether it is an intermediate “stop” for classical monocytes
as they shift toward a non-classical monocytes phenotype.
Of importance, “classical” monocytes are featured by
a distinct proinﬂammatory phenotype, and their high counts
are associated with poor myocardial recovery and worse
outcome after MI (71). Although inﬂammatory stress
associated with these cells is usually mentioned in the
context of their potentially detrimental effects, the role of
these cells is by far more complex and includes a number of
potentially beneﬁcial properties, including: phagocytic
activity; and regulation of extracellular matrix turnover. An
appropriate balance in numbers and functional activity as
well as in timing in relation to MI onset is probably the key
in relation to the role of the cells in acute coronary
Figure 2 Hypothesized Principles of Pharmaceutical Targeting of Monocyte Subpopulations in the Healing Myocardium
The exact role of CD14þþCD16þCCR2þ (Mon2) cells remain unclear; more data are required. However, because they are associated in humans with low ejection fraction after
recovery from ST-segment elevation myocardial infarction, it could be postulated that they have a role in debris removal early in the healing process. Nonetheless, their surface
expression of Tie-2 is suggestive of a role in angiogenesis and reparation.
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1547catastrophes. However, this perspective is based on numer-
ical quantiﬁcation and presence of monocytes as opposed to
assessment of function, not to mention that the role of the
“intermediate” and “non-classical” monocytes is still to be
deciphered.
The role of progenitor cells in wound healing and cardiac
remodeling is currently the object of intense scientiﬁc
interest. Infusion of mesenchymal cells into the mouse
myocardium 48 h after MI induction reduced overall
myocardial macrophage/monocyte levels. This included pro-
inﬂammatory M1-type macrophages, whereas alternatively
activated M2-type macrophages were signiﬁcantly in-
creased both in the circulation and the heart (72). Delivery
of the mesenchymal cells resulted in: reduced cardiac
expression of IL-1b; reduced expression of IL-6; increased
anti-inﬂammatory IL-10 expression without changes in
angiogenesis in the infarct area; and improved cardiac
systolic function (72). This could suggest that mesenchymal
cells might regulate the switch in monocyte/macrophage
phenotype toward M2 polarization and favorable remodel-
ing post-infarction.
Of interest, Kuwana et al. (73) described CD14þ
monocyte-derived mesenchymal progenitors that can
differentiate into a variety of mesenchymal cell types as well
as having phagocytic function, thus providing a possible
cellular source for tissue regeneration including wound
healing and potentially heart remodeling. Also, monocyte-
derived progenitor cells have been implicated in cardiac
allograft vasculopathy, likely due to their ability to differ-
entiate into smooth muscle cells and promote intimal
hyperplasia (74). However, it is important to note that this
group of patients routinely receive anti-rejection medication,
and it remains to be seen whether this has an effect on the
abundance of monocyte-derived progenitor cells (74).
To address the potential role for inﬂammation in tissue
damage post-MI, steroid therapy was used in the 1970s and
1980s in acute MI but has not produced the anticipated
beneﬁcial effect and failed to show an improvement in
clinical outcome post-STEMI (75,76). This might be partlydue to creating an imbalance between the different mono-
cyte subpopulations eradicating both the inﬂammatory as
well as the reparative subtypes, altering the downstream
differentiation of monocytes or potentially disturbing the
cross talk between DC, monocytes, and macrophages.
Hence, targeting speciﬁc subpopulations at appropriate
phases of cardiac healing/remodeling is a theoretical alter-
native to improve outcome of inﬂammatory events post-MI
(Fig. 2).
Interestingly, successful stem cell therapy in STEMI has
been based on intracoronary administration of bone marrow
mononuclear cells, which include a large proportion of
monocytes (Table 2). However, none of the studies used
puriﬁed monocyte-derived progenitor cells but rather used
a total pool of mononuclear progenitors.
Perhaps delivery or modulation of speciﬁc monocyte
subpopulations at different stages of healing will form the
basis of future regenerative cell therapy after MI. Indeed,
Leor et al. (77) have shown that administration of activated
human macrophages to the ischemic myocardium in rats
accelerated vascularization and repair of the infarcted
myocardium with improved cardiac remodeling and systolic
function.Where Are We Now?
No doubt monocytes play an important role in the patho-
physiology of CAD and its complication. Blood monocytes
are easier to detect and characterize, compared with tissue
macrophages. As medical practice moves into the 21st
century with more emphasis on the prediction and
prophylaxis of future acute events, monocyte numbers and
functions might become a very attractive biomarker.
However, the key monocyte parameters with a potential to
become prognostic markers and treatment targets are still to
be deﬁned and validated.
Indeed, there are still gaps in our knowledge of how
monocytes differentiate into speciﬁc type ofmacrophages/DC
in coronary plaques and later within infarcted tissue and
Table 2
Summary of Clinical Trials Using Bone Marrow Mononuclear Cells in Acute Coronary Syndrome Patients With
Summary of Trial Findings
Study/First Author
(Ref. #) Methodology Study Period
Study Population
(Intervention/Control Group) Results




60 (30/30) Compared with control group, patients
treated with BMNC exhibited: improved
contractility of infarcted area; reduced
mortality; improved exercise
REPAIR-AMI (79) BMPC infusion into culprit vessel
3–7 days post-AMI
12 months 204 In patients vs. placebo: BMPC administration
was a signiﬁcant predictor of a favorable
outcome; cumulative endpoints of death,
recurrence of MI, or revascularization or
hospital stay for heart failure signiﬁcantly
reduced
BOOST (80) BMNC intracoronary
4 days post-AMI
6 and 8 months 60 (30/30) Increased global EF in intervention group
(6% at 6 months)
Effect between intervention group and
control group lost at 18 months; however,
improved EF retained among transmural
infarct group
Jannsens et al. (81) BM stem cells intracoronary
24 h post-AMI
4 months 67 (33/34) No improvement in EF
ASTAMI (82) BMNC intracoronary 3 years 100 (50/50) The results indicate that intracoronary
BMNC treatment in AMI is safe in the long
term; a small improvement in exercise time
in the BMNC group was found, but no effects
of treatment on global LV systolic function
Traverse et al. (83) BMNC intracoronary
at day 310
6 months 40 (30/10) No difference in EF between groups; BMNC
group had improved remodeling with
signiﬁcantly lower LVEDV
AMI¼ acute myocardial infarction; ASTAMI¼ Autologous Stem Cell Transplantation in Acute Myocardial Infarction trial; BALANCE¼ Bone Marrow Cell Transplantation in Patients with Acute. Myocardial Infarction
study; BM¼ bonemarrow; BMNC¼ bonemarrowmononuclear cells; BMPC¼ bonemarrowprogenitor cells; BOOST¼BOnemarrOw transfer to enhanceST-elevation infarct regeneration trial; EF¼ ejection fraction;
LV ¼ left ventricle; LVEDV¼ left ventricular end diastolic volume; PC¼ progenitor cells; REPAIR-AMI¼ Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction trial.
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1548their role in regulating post-infarct reparative processes. The
preferential differentiation of certain monocyte populations
into particular macrophage types and other cells (e.g., myo-
ﬁbroblasts) has been suggested but needs further evidence.
The understanding of the function of intermediate
monocytes is still in its early days. This venture will be
blighted with practical difﬁculties: namely, the isolation of
the small amounts of intermediate monocytes from whole
blood, then maintaining cell viability (without differentia-
tion) to allow characterization of their function and down-
stream inﬂammatory pathway activation. A multitude of
murine/animal models could be used, but ultimately devel-
opment of new high-resolution molecular in vivo imaging
techniques to tag and track monocytes is needed. This will
provide valuable information on mechanisms and magnitude
of mobilization of individual monocyte subsets to the
myocardium and their differentiation and might shed
further light on intimate aspects of monocyte activities that
might prove to be new therapeutic targets.
The role of the microenvironment and local factors in
driving monocyte differentiation both in the sub-endothelial
space and in the infarcted tissue also need to be further
elucidated. Furthermore, detailed exploration of monocyte
action via interaction and in coordination with other cells,
such as lymphocytes and platelets, and in relation to
different progenitor and stem cells is deserved.
The expression of chemokine receptors on the surface of
infarcted cardiomyocytes is essential to be studied, even onanimal models (e.g., porcine hearts, the most closely related
species anatomically and physiologically to human hearts).
If therapeutic agents could modulate the expression of
MCP-1, fractalkine, or CCR5, then monocytes subpopu-
lations could be attracted to infarcted tissues earlier, leading
to concurrent removal of debris, angiogenesis, ﬁbroblast
deposition, and better myocardial recovery.
Study limitations. Inﬂammation might be the “new kid on
the block” in atherosclerosis and ACS. However, it is
important not to forget the complex interaction between
platelets, the clotting pathways, as well as other components
of the immune system, including T-cells at the time of an
ACS. More information is needed on the effect of the
myriad of antiplatelet therapies administered during ACS on
monocytes, their function and differentiation potential.
Most of our current information is provided from peripheral
sampling in murine, in vivo, or human studies. Hence,
“direct” coronary sampling and “live” visualization of the
ruptured and unstable plaque, via hybrid intracoronary
spectroscopy and intravascular ultrasound will soon be
available in the research and clinical arena, providing valu-
able local interrogation of lipid cores, ﬁbrous cap, mono-
cytes, and their microenvironment in different clinical
settings. Ventricular remodeling post-infarct is greatly
inﬂuenced by the neuro-hormonal cascade, namely aldo-
sterone. Hence, the interaction(s) of this system with
inﬂammation at the time of infarction and ensuing period
are yet to be fully elucidated.
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1549Conclusions
Multiple essential roles are played by monocytes during the
various stages of atherosclerosis, from its initiation to the
progression and development of its complications and later
on, during myocardial healing and remodeling. These
different roles can provide a fertile ground for pharmaco-
logical modulation of atherogenesis, stabilization of the
atherosclerotic plaque, or more importantly in myocardial
healing and post-infarction remodeling.
Monocyte-mediated pathways are not limited to the
cardiovascular system, and inhibition of any of the
surroundingmilieu of cellular mechanisms could actually alter
this ﬁnely tuned balance in other inﬂammatory systems
leading to deleterious side effects. Hence, direct targeting
of speciﬁc monocyte subpopulations at different sites and
stages of MI would seem to be the best option. In fact, stem
cell therapy relying largely on monocyte subpopulations
renders an attractive potential. Given that most of our current
knowledge in the ﬁeld comes from murine models, further
clinical studies are clearly required to improve our under-
standing of monocyte pathophysiology in human cardiac
damage post-ACS and the subsequent remodeling and
recovery of the myocardium.
Whichever way we appraise our current knowledge about
origin and progression of atherosclerosis, we are drawn to
the same common origin: monocytes, their subpopulations,
their function, and their differentiation. With multiple
therapeutic agents targeting “the clot” during ACS, an
alternate and most attractive target for therapy lies in
inﬂammation and particularly speciﬁc monocytes subpopu-
lations with their diverse phenotypes and sentinel role in
both the innate and adaptive immune system.
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